Gabather has initiated its first patient study with drug candidate GT-002 in schizophrenia, a phase II study targeting cognitive symptoms in an area with significant unmet need and no approved pharmacological treatments. With a recently completed capital raise and a clearly stated ambition to sign a licensing deal in 2026, BioStock reached out to CEO Michael-Robin Witt to learn more.
Read more